Bevacizumab biosimilar：7.5mg/kg，IV，D1，Q2W FOLFOX4：~Oxaliplatin: 85 mg/m2 , IV, D1，Q2W~Calcium leovorin: 200 mg/m2 ,IV, D1、D2，Q2W~Fluorouracil: 400 mg/m2 push infusion and given 600mg/m2 intravenously 22 hours later， D1、D2, Q2W
This study is a single arm, single center, prospective and open exploratory study.~About 15 patients with recurrent hepatocellular carcinoma (HCC) after liver transplantation are expected to be enrolled.Patients will be treated with bevacizumab and FOLFOX4.Treatment was continued until disease progression, development of intolerable toxicities, death, withdrawal of consent, initiation of new antitumor therapy, whichever occurred first.